Neurocognitive and neuroanatomical changes in children with acute lymphoblastic leukemia treated with the modified BFM-95 protocol

被引:0
|
作者
Chidambaram, Sundaramoorthy [1 ]
Elangovan, Vidhubala [1 ]
Mahajan, Vandana [2 ]
Ganesan, Prasanth [3 ]
Radhakrishnan, Venkatraman [3 ]
机构
[1] Canc Inst WIA, Dept Psychooncol, 38 Sardar Patel Rd, Chennai 600036, Tamil Nadu, India
[2] Canc Inst WIA, Dept Radiol, Chennai, Tamil Nadu, India
[3] Canc Inst WIA, Dept Med Oncol, Chennai, Tamil Nadu, India
关键词
Acute lymphoblastic leukemia; BFM-95; protocol; central nervous system prophylactic treatment; chemotherapy; childhood cancer; cranial irradiation; neuropsychological functioning; LONG-TERM SURVIVORS; CRANIAL IRRADIATION; CHILDHOOD LEUKEMIA; CHEMOTHERAPY; CANCER; CNS; METHOTREXATE; EXPERIENCE; INDIA; NEUROTOXICITY;
D O I
10.4103/ijmpo.ijmpo_138_18
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The use of cranial radiotherapy for central nervous system (CNS) prophylaxis in children with acute lymphoblastic leukemia (ALL) is debated owing to its effect on neurocognitive functioning, as only <30% of the patients present with low risk in India and majority of the patients with high risk have to be treated with cranial radiation therapy (CRT) to prevent relapse. Given the increasing number of ALL survivors in India, the effect of CRT on neurocognitive functioning in children with ALL needs to be studied. Methods: Children (n = 44) with ALL who received CRT, intrathecal methotrexate (IT-MTX), and high-dose methotrexate (HD-MTX) for CNS prophylaxis as part of the modified Berlin-Frankfurt-Munster 95 protocol were included. Neurocognitive assessments and magnetic resonance image were performed to assess neurocognitive functioning and neuroanatomical structures, respectively. Five assessments were performed during the induction, end of re-induction I and II, commencement of maintenance, and end of maintenance phases of the modified BFM-95 protocol. Neurocognitive data of children with ALL were compared with those of healthy children (n = 60) at the baseline and after the final assessment. Results: A significant deterioration was observed in the performance intelligence, visuospatial ability, processing speed, and verbal retention domains after the completion of CNS prophylaxis. Three children had white matter changes on magnetic resonance imaging and showed reduced functioning in performance intelligence quotient, working memory, visual immediate and delayed memory, processing speed, verbal retention, visuospatial ability, processing speed, attention, planning and fine motor skills, and verbal comprehension. Children with ALL had poorer neuropsychological functioning when compared with healthy children. Conclusion: CNS prophylactic therapy as part of the BFM-95 protocol had an adverse effect on the neuropsychological functioning of children with ALL, and the effect was more pronounced when CRT was added to the treatment.
引用
收藏
页码:222 / 231
页数:10
相关论文
共 50 条
  • [31] Bleeding and thrombosis in children with acute lymphoblastic leukaemia, treated according to the ALL-BFM-90 protocol
    Sutor, AH
    Mall, V
    Thomas, KB
    KLINISCHE PADIATRIE, 1999, 211 (04): : 201 - 204
  • [32] Clinical Features and Prognostic Significance of TCF3-PBX1 Fusion Gene in Chinese Children with Acute Lymphoblastic Leukemia by Using a Modified ALL-BFM-95 Protocol
    Pang, Li
    Liang, Ying
    Pan, Jian
    Wang, Jian-Rong
    Chai, Yi-Huan
    Zhao, Wen-Li
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2015, 32 (03) : 173 - 181
  • [33] Acute and sub-acute neurological toxicity in children treated for acute lymphoblastic leukemia
    Millan, Natalia C.
    Pastrana, Analia
    Guitter, Myriam R.
    Zubizarreta, Pedro A.
    Monges, Maria S.
    Felice, Maria S.
    LEUKEMIA RESEARCH, 2018, 65 : 86 - 93
  • [34] Oxidative Stress, Motor Abilities, and Behavioral Adjustment in Children Treated for Acute Lymphoblastic Leukemia
    Hockenberry, Marilyn J.
    Krull, Kevin R.
    Insel, Kathleen C.
    Harris, Lynnette L.
    Gundy, Patricia M.
    Adkins, Kristin B.
    Pasvogel, Alice E.
    Taylor, Olga A.
    Koerner, Kari M.
    Montgomery, David W.
    Ross, Adam K.
    Hill, Adam
    Moore, Ida M.
    ONCOLOGY NURSING FORUM, 2015, 42 (05) : 542 - 549
  • [35] Acute lymphoblastic leukemia: A single center experience with Berlin, Frankfurt, and Munster-95 protocol
    Radhakrishnan, Venkatraman
    Gupta, Sumant
    Ganesan, Prasanth
    Rajendranath, Rejiv
    Ganesan, Trivadi S.
    Rajalekshmy, Kamalalayan Raghavan
    Sagar, Tenali Gnana
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2015, 36 (04) : 261 - 264
  • [36] Specific learning problems among children treated for acute lymphoblastic leukemia
    Cousens, P
    INTERNATIONAL JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY, 1997, 4 (04): : 353 - 362
  • [37] Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study
    Dujua, Amanda Christina C.
    Hernandez, Flerida G.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2017, 39 (03) : E116 - E123
  • [38] WHITE MATTER CHANGES IN CHILDREN TREATED FOR ACUTE LYMPHOBLASTIC-LEUKEMIA
    PAAKKO, E
    VAINIONPAA, L
    LANNING, M
    LAITINEN, J
    PYHTINEN, J
    CANCER, 1992, 70 (11) : 2728 - 2733
  • [39] Correlation of Day 8 Steroid Response with Bone Marrow Status Measured on Days 14 and 35, in Patients with Acute Lymphoblastic Leukemia Being Treated with BFM Protocol
    Kamat, Girish
    Subramanian, Kannan
    Apte, Shashikant
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2019, 35 (04) : 635 - 639
  • [40] Neurocognitive outcomes among children who experienced seizures during treatment for acute lymphoblastic leukemia
    Nassar, Stephanie L.
    Conklin, Heather M.
    Zhou, Yinmei
    Ashford, Jason M.
    Reddick, Wilburn E.
    Glass, John O.
    Laningham, Fred H.
    Jeha, Sima
    Cheng, Cheng
    Pui, Ching-Hon
    PEDIATRIC BLOOD & CANCER, 2017, 64 (08)